ArticlePharmacoEconomics2023

Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.

Chen-Han Chueh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.